background: in recent years, the success in management of thalassemic patients, has allowed for some previously unrecognized complications including renal abnormalities to emerge. this prospective study aimed to investigate kidney iron overload by means of mri t2* and also renal function based on laboratory tests for early markers of glomerular and tubular dysfunction among adult iranian transf...

background: transfusion is the mainstay treatment of patients with thalassemia major and occasionally in thalassemia intermediate. alloimmunization is an unwanted side effect of blood transfusion. the present study intended to determine the frequency of alloimmunization in patients with β- thalassemia major and thalassemia intermediate in southwest iran. patients and methods: this was a cross-s...

conclusions: hydroxyurea can be safely used in some transfusion-dependent β-thalassemia patients to decrease their transfusion needs. background: β-thalassemia is an inherited hemoglobin disorder caused by defective synthesis of ß-globin chains. hemoglobin (hb) f induction is a possible therapeutic approach which can partially compensate for α and non-α globin chains imbalance. objectives: we a...

Advances in the management of transfusion dependent thalassemic patients have improved the survival of these patients. The most important consequence of repeated and frequent transfusions is iron accumulation in vital organs. The magnetic resonance imaging (MRI) is a non-invasive and valid technique for the estimation of iron stores. Despite multiple studies about cardiac and liver MRI T2*, the...

Background: The development of anti-red blood cell alloantibodies remains a major problem in transfusion of blood in thalassemia major patients. Also, Autoantibodies can result in clinical hemolysis and difficulty in cross-matching blood. We studied the frequency of red blood cell alloimmunization and autoimmunization among thalassemia patients who received regular transfusions in Ilam province...

Non-transfusion-dependent thalassemias include a variety of phenotypes that, unlike patients with beta (β)-thalassemia major, do not require regular transfusion therapy for survival. The most commonly investigated forms are β-thalassemia intermedia, hemoglobin E/β-thalassemia, and α-thalassemia intermedia (hemoglobin H disease). However, transfusion-independence in such patients is not without ...

background: the classical supportive therapy for î² -thalassemia major consists of regular blood transfusion, iron-chelation therapy and specific treatment of the related complications. a balance between the maintenance of the highest possible level of haemoglobin and lowest possible level of iron accumulation in heart and liver give the best chance of survival and the best quality of life. met...

Background: Beta thalassemia gene mutations are among common mutations in southwest Iran. However, Hemoglobin E (Hb E) and Hb E/β⁰ thalassemia account for a small number of hemoglobinopathies in Iran. This is the first study to directly address the existence of Hb E and consequently Hb E/β⁰ thalassemia in southwest Iran. Methods: This retrospective study discovered seven cases of Hb E/β⁰ thal...